General Information of Drug (ID: DMVUKEW)

Drug Name
N-methylpyridinium Drug Info
Synonyms 1-Methyl-Pyridinium; 1-Methylpyridin-1-ium; 1-Methylpyridinium; N-Methylpyridinium; Pyridinium, 1-methyl-
Indication
Disease Entry ICD 11 Status REF
Colon cancer 2B90.Z Preclinical [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
13597
ChEBI ID
ChEBI:15761
TTD Drug ID
DMVUKEW
VARIDT Drug ID
DR00337

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTP
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [6]
Cisplatin DMRHGI9 Solid tumour/cancer 2A00-2F9Z Approved [7]
Oxaliplatin DMQNWRD Colorectal cancer 2B91.Z Approved [8]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [9]
Dopamine DMPGUCF Parkinson disease 8A00.0 Approved [10]
Propranolol DM79NTF Migraine 8A80 Approved [11]
Ergotidine DM78IME Respiratory allergy 4A80 Approved [12]
Metformin DM89QE1 Type-2 diabetes 5A11 Approved [13]
Clonidine DM6RZ9Q Hypertension BA00-BA04 Approved [11]
Ranitidine DM0GUSX Peptic ulcer DA61 Approved [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aciclovir DMYLOVR Virus infection 1A24-1D9Z Approved [4]
Metformin DM89QE1 Type-2 diabetes 5A11 Approved [15]
Ganciclovir DM1MBYQ Virus infection 1A24-1D9Z Approved [4]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [4]
Chloroquine DMSI5CB Malaria 1F40-1F45 Approved [16]
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [4]
Topotecan DMP6G8T Ovarian cancer 2C73 Approved [4]
Cephalexin DMD5JU8 Bacterial infection 1A00-1C4Z Approved [17]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [18]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [19]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propranolol DM79NTF Migraine 8A80 Approved [11]
Ergotidine DM78IME Respiratory allergy 4A80 Approved [10]
Metformin DM89QE1 Type-2 diabetes 5A11 Approved [20]
Clonidine DM6RZ9Q Hypertension BA00-BA04 Approved [11]
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [21]
Epinephrine DM3KJBC Allergy 4A80-4A85 Approved [10]
Norepinephrine DMOUC09 Sepsis 1G40-1G41 Approved [10]
Amphetamine DMSZQAK Attention deficit hyperactivity disorder 6A05.Z Approved [22]
Acetylcholine DMDF79Z Cataract 9B10 Approved [23]
Sodium chloride DMM3950 Skin burns ME65.0 Approved [24]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [6]
Cisplatin DMRHGI9 Solid tumour/cancer 2A00-2F9Z Approved [25]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [26]
Oxaliplatin DMQNWRD Colorectal cancer 2B91.Z Approved [27]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [28]
Verapamil DMA7PEW Hypertension BA00-BA04 Approved [29]
Sorafenib DMS8IFC Hepatocellular carcinoma 2C12.02 Approved [30]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [31]
Dopamine DMPGUCF Parkinson disease 8A00.0 Approved [32]
Propranolol DM79NTF Migraine 8A80 Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aciclovir DMYLOVR Virus infection 1A24-1D9Z Approved [4]
Metformin DM89QE1 Type-2 diabetes 5A11 Approved [4]
Ganciclovir DM1MBYQ Virus infection 1A24-1D9Z Approved [4]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [4]
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [4]
Topotecan DMP6G8T Ovarian cancer 2C73 Approved [4]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [18]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [19]
Estrone sulfate DMVBIZL Menopausal and postmenopausal disorder GA30 Approved [4]
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 3 (SLC22A3) DT6201N S22A3_HUMAN Substrate [2]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [3]
Multidrug and toxin extrusion protein 2 (SLC47A2) DT3TX4H S47A2_HUMAN Substrate [4]
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [4]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [5]

References

1 Wikipedia: Methylpyridinium
2 Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58.
3 Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008 Jun;57(6):1463-9.
4 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
5 Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009 Jun;37(6):1312-8.
6 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
7 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
8 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
9 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
10 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
11 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
12 The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
13 Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
14 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
15 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
16 Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
17 Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
18 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
19 FDA Drug Development and Drug Interactions
20 Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40.
21 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
22 Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9.
23 Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31.
24 Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci. 2004 Mar 17;24(11):2846-51.
25 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
26 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
27 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
28 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
29 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
30 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
31 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
32 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.